Disease · MONDO_0008327

exfoliation syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. exfoliation syndrome. Diseases, record MONDO_0008327. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008327

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: exfoliation syndrome; Open Targets
Open Targets ID: MONDO_0008327; Open Targets
Other names: Glaucoma Capsulare, XFG, XFS, exfoliation glaucoma, exfoliative syndrome, pseudo-exfoliation syndrome, pseudoexfoliation glaucoma, pseudoexfoliation syndrome; Open Targets
Disease Ontology: DOID:13641; Disease Ontology
MeSH: D017889; MeSH
NCI Thesaurus: C129025; NCI Thesaurus
Orphanet: ORPHA:529819; Orphanet
Highest stage of its drugs: Phase 2, for 1 of its 8 drugs, from ClinicalTrials.gov; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
VEROSUDIL	CHEMBL3545065	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LATANOPROST	CHEMBL1051	Small molecule	Unknown	ClinicalTrials.gov	2	2	2	Drugs and targets
BRIMONIDINE TARTRATE	CHEMBL1200389	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
BRINZOLAMIDE	CHEMBL220491	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
DORZOLAMIDE	CHEMBL218490	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
PILOCARPINE	CHEMBL550	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
TIMOLOL	CHEMBL499	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
TRAVOPROST	CHEMBL1200799	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets11

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CA2	Carbonic anhydrase 2	2	Carbonic anhydrase II inhibitor	Unknown	https://conductscience.org/library/genes/760	Drugs and targets
PTGFR	Prostaglandin F2-alpha receptor	2	Prostanoid FP receptor agonist	Unknown	https://conductscience.org/library/genes/5737	Drugs and targets
ADRA2A	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Unknown	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Unknown	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Unknown	https://conductscience.org/library/genes/152	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	1	Beta-1 adrenergic receptor antagonist	Unknown	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	1	Beta-2 adrenergic receptor antagonist	Unknown	https://conductscience.org/library/genes/154	Drugs and targets
CHRM1	Muscarinic acetylcholine receptor M1	1	Muscarinic acetylcholine receptor M1 agonist	Unknown	https://conductscience.org/library/genes/1128	Drugs and targets
CHRM3	Muscarinic acetylcholine receptor M3	1	Muscarinic acetylcholine receptor M3 agonist	Unknown	https://conductscience.org/library/genes/1131	Drugs and targets
ROCK1	Rho-associated protein kinase	1	Rho-associated protein kinase inhibitor	Phase 2	https://conductscience.org/library/genes/6093	Drugs and targets

1 to 10 of 11

See all 11 targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01936389	A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma	Phase 2	10	2015-04-24	Exfoliation Syndrome, Ocular Hypertension, Open Angle Glaucoma	VEROSUDIL	Its record names the disease	ClinicalTrials.gov
NCT00804115	The International Collaborative Exfoliation Syndrome Treatment Study	Not applicable	277		Exfoliation Syndrome, Glaucoma, Ocular Hypertension	LATANOPROST, PILOCARPINE	Its record names the disease	ClinicalTrials.gov
NCT00121147	Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan	Not applicable	200		Open Angle Glaucoma, Ocular Hypertension, Pseudoexfoliation Syndrome	BRIMONIDINE TARTRATE, BRINZOLAMIDE, TRAVOPROST	Its record names the disease	ClinicalTrials.gov
NCT00440336	Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.	Not applicable	30		Open Angle Glaucoma	DORZOLAMIDE, LATANOPROST, TIMOLOL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
0.5% vs 0.7%: serious adverse events	0 of 5	0 of 5	10	NCT01936389

Source Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0008327

GET https://conductscience.org/api/diseases/v1/MONDO_0008327/drugs

API reference For AI assistants